SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nazisa Hejazi, Roslee Rajikan, Health of HIV Infected People, 2015,

    CrossRef

  2. 2
    S. Srinivasa, S. K. Grinspoon, MECHANISMS IN ENDOCRINOLOGY: Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients, European Journal of Endocrinology, 2014, 170, 5, R185

    CrossRef

  3. 3
    Suelen Jorge Souza, Liania Alves Luzia, Sigrid Sousa Santos, Patrícia Helen Carvalho Rondó, Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review, Revista da Associação Médica Brasileira (English Edition), 2013, 59, 2, 186

    CrossRef

  4. 4
    Suelen Jorge Souza, Liania Alves Luzia, Sigrid Sousa Santos, Patrícia Helen Carvalho Rondó, Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review, Revista da Associação Médica Brasileira, 2013, 59, 2, 186

    CrossRef

  5. 5
    Denise C Hsu, Irini Sereti, Jintanat Ananworanich, Serious Non-AIDS events: Immunopathogenesis and interventional strategies, AIDS Research and Therapy, 2013, 10, 1, 29

    CrossRef

  6. 6
    Hazel Jones-Parker, Primary, Secondary, and Tertiary Prevention of Cardiovascular Disease in Patients With HIV Disease: A Guide for Nurse Practitioners, Journal of the Association of Nurses in AIDS Care, 2012, 23, 2, 124

    CrossRef

  7. 7
    Christoph Stephan, Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature, Expert Opinion on Pharmacotherapy, 2012, 13, 16, 2355

    CrossRef

  8. 8
    Allison C Ross, Grace A McComsey, Assessment and modification of cardiovascular disease risk in the HIV-infected individual, Future Virology, 2011, 6, 3, 307

    CrossRef

  9. 9
    Allison C Ross, Grace A McComsey, Cardiovascular Disease Risk in Pediatric HIV: The Need for Population-Specific Guidelines, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011, 57, 5, 351

    CrossRef

  10. 10
    Denise L Jacobson, Paige Williams, Katherine Tassiopoulos, Ann Melvin, Rohan Hazra, John Farley, Clinical Management and Follow-up of Hypercholesterolemia Among Perinatally HIV-Infected Children Enrolled in the PACTG 219C Study, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011, 57, 5, 413

    CrossRef

  11. 11
    M. Aboud, A. Elgalib, L. Pomeroy, G. Panayiotakopoulos, E. Skopelitis, R. Kulasegaram, C. Dimian, F. C Lampe, A. Duncan, A. S. Wierzbicki, B. S. Peters, Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study, International Journal of Clinical Practice, 2010, 64, 9
  12. 12
    R Rubio, O Serrano, J Carmena, V Asensi, S Echevarría, J Flores, E Ribera, M Zarraga, A Ocampo, B De La Fuente, MA Sepúlveda, AI Mariño, C Minguez, R Vicent, JA Cartón, B Moyano, H Esteban, B Mahillo, L Serrano, J González-García, Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions, HIV Medicine, 2010, 11, 9
  13. 13
    Sara Melzi, Laura Carenzi, Maria Vittoria Cossu, Simone Passerini, Amedeo Capetti, Giuliano Rizzardini, Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems, Cholesterol, 2010, 2010, 1

    CrossRef

  14. 14
    Paul Randell, Graeme Moyle, Antiretroviral Therapy With Heart, American Journal of Therapeutics, 2009, 16, 6, 579

    CrossRef

  15. 15
    Danièle Bentué-Ferrer, Cédric Arvieux, Olivier Tribut, Annick Ruffault, Eric Bellissant, Clinical pharmacology, efficacy and safety of atazanavir: a review, Expert Opinion on Drug Metabolism & Toxicology, 2009, 5, 11, 1455

    CrossRef

  16. 16
    Laura Zamora, José María Gatell, Atazanavir en el tratamiento de simplificación, Enfermedades Infecciosas y Microbiología Clínica, 2008, 26, 14

    CrossRef

  17. 17
    Robin Wood, Atazanavir: its role in HIV treatment, Expert Review of Anti-infective Therapy, 2008, 6, 6, 785

    CrossRef

  18. 18
    Esteban Martínez Chamorro, Perfil lipídico de atazanavir, Enfermedades Infecciosas y Microbiología Clínica, 2008, 26, 34

    CrossRef

  19. 19
    Christoph Boesecke, David A Cooper, Toxicity of HIV protease inhibitors: clinical considerations, Current Opinion in HIV and AIDS, 2008, 3, 6, 653

    CrossRef

  20. 20
    Esteban Ribera Pascuet, Adrià Curran, Utilidad clínica de atazanavir, Enfermedades Infecciosas y Microbiología Clínica, 2008, 26, 55

    CrossRef